In recent years, many inhibitors that target RNA modifications, such as small-molecule inhibitors of FTO and ALKBH5, which inhibit immune escape from tumors by targeting m6A modifications to inhibit the growth of many cancers, have been developed and investigated in clinical studies [70, 71]. The gene discussed is FTO; the disease is cancer.